Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. It also provides technical services such as drug development, including the development and quality research of active pharmaceutical ingredients (APIs) and formulation processes. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzhou, China.
Research context
Fujian Cosunter Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Fujian Cosunter Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 1.0% above its 200 day moving average.
From a valuation standpoint, the stock is 43.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Fujian Cosunter Pharmaceutical Co., Ltd's total revenue rose by 5.8% to $98M since the same quarter in the previous year.
Its net income has increased by 94.3% to $-188K since the same quarter in the previous year.
Finally, its free cash flow fell by 98.2% to $-16M since the same quarter in the previous year.
Based on the above factors, Fujian Cosunter Pharmaceutical Co., Ltd gets an overall score of 3/5.